Repsol is a global multi-energy provider, which works to facilitate the transition towards an energy model with fewer emissions. It employs over 25,000 people, has assets in 35 countries, and sells its products to 10 million customers in more than 90 countries. It operates low-emission power generation assets and is developing various renewable photovoltaic and wind energy projects. The company is a pioneer in the development of initiatives for sustainable mobility with more efficient fuels and new solutions. It produces more than 700,000 barrels of oil equivalent per day. Technology and digitalization are pillars of the company, whose objective is to be zero net emissions in 2050, the first in the sector to assume this ambitious goal.

The company is committed to its customers’ global strategy putting their entire organization at their disposal to achieve a common goal: to create long-term relationships that enable them to rise to the everyday challenges the business presents.

Repsol manufactures and markets a wide variety of chemical products, ranging from basic petrochemicals to derivatives. Repsol’s derivative chemicals include a broad range of polyolefins. Repsol is the first polyolefins producer to obtain the FSCC 22000 food safety certification in all their industrial complexes. In January 2018, they already received this certification for all plastic polymers produced at their Tarragona industrial site. The first-ever granted to a polyolefin production center worldwide, which was later followed by their Puertollano and Sines complexes in December 2018 and March 2019, respectively.

The company's Repsol Healthcare^® range currently encompasses 35 different polyolefin grades produced in designated and upgraded "pharma units" that apply particular protocols and training.

Their goal is to manufacture and sell polyolefins for pharmaceutical packaging and medical devices, offering the maximum quality, service, commitment and compliance worldwide, keeping the patients’ safety as their number one priority.

The medical devices market is a highly innovative field, which seeks to meet the patients’ needs and improve comfort and well-being with new designs. The raw materials must comply with different regulations and be tested in different conditions before approval in order to warrant the safety of use – all of which makes entry into the market of anew player a slow-moving process.

Repsol’s latest addition to its range for pharmaceutical packaging and medical devices of new LDPE gradesthat offer convertors a wide variety of alternatives designed to meet their needs as regards both melt flow index (0.3–20 g/10’) and density. These new grades allow converters to manufacture novel containers, parts and films using lamination, blown film extrusion and injection.

The extension to the range has been possible thanks to the addition of the company’s LDPE plant in Sines, Portugal, to the Repsol pharma family, joining the units in Tarragona — where it produces polypropylene (PP), low-density polyethylene (LDPE) and high-density polyethylene (HDPE) — and Puertollano, which makes ethylene-vinyl acetate (EVA) copolymers.

Repsol has upgraded some of its production units, in order to assure the best quality. They have also established new protocols and operations to meet the best practices of the health industry as well as its demands for quality and hygiene.

Repsol’s chemicals division focuses its strategy on the constant generation of value through differentiated products and services.